Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

• Asıl Yazarlar: Alexandra B. Kimball (Yazar), Thomas Luger (Yazar), Alice Gottlieb (Yazar), Luis Puig (Yazar), Roland Kaufmann (Yazar), Russel Burge (Yazar), Chen-Yen Lin (Yazar), Gil Yosipovitch (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Medical Journals Sweden, 2017-10-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance thera...